Circulating tumor cell chromosomal instability and neuroendocrine phenotype by immunomorphology and poor outcomes in men with mCRPC treated with abiraterone or enzalutamide.

While the detection of the AR-V7 in CTCs is associated with resistance to abiraterone or enzalutamide (abi/enza) in men with metastatic castration resistant prostate cancer (mCRPC), it only accounts for a minority of this resistance.